News

  • Sep 6, 2010

    Circadin® use approved for up to 3 months in Croatia

  • Jul 5, 2010

    Circadin® approved in the EU for treatment of Primary Insomnia in patients aged 55 or over for up to 3 months (Read more)

  • Apr 22, 2010

    EMEA approves Circadin® use for up to 3 months

  • Jun 11, 2009

    Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin® for Insomnia in Elderly Patients (Read more)

  • Sep 24, 2007

    Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck

  • Jul 6, 2007

    Nycomed to market Circadin® for primary insomnia (Read more)

  • Jun 29, 2007

    An Authorisation valid throughout the European Union was issued by the EMEA for Circadin®

  • Apr 27, 2007

    Neurim Pharmaceuticals announce that Circadin® for Primary Insomnia is recommended for approval in the EU (Read more)

  • Apr 26, 2007

    Summary of positive opinion for Circadin® (EMEA Press Release) (Read more)

  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
    • NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD)
    • Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018
  • Partners

    Partners